Kairos Pharma reports positive trial data
- Interim PFS of 17.7 months with ENV-105 + apalutamide vs 2 months with apalutamide alone
- Trial protocol modified to enroll patients earlier in disease progression
- Phase 2 trial targeted for completion by Q4 2027